Contents
Issue 126 • January 2023
In association with
In association with
In Depth
Humira biosimilars set the stage for long-awaited 2023 US launches
Expanding ketamine’s horizons for rare neurological disorders
The “Medical Bypass”: New drugs to strike obesity
Running low on comparators: drug shortages in oncology clinical trials
ACT EU state of play: EMA’s headway to transform clinical trials
CMO Moves: Regulatory catalysts for drug manufacturing-December
Comment
Cannabinoids receptors: popular preclinical target but banned in 137 countries
Ozempic compensating for Wegovy’s supply shortage due to high demand
Manufacturing challenges set back progress of cell therapies in oncology
Chinese manufacturers’ transition to innovative pharma needs more investment
DLBCL: a rapidly evolving treatment landscape with a crowded pipeline